Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-292 in HR-positive/HER2-negative advanced breast cancer
CTR20232765Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capivasertib, fulvestrant, palbociclib, ribociclib in breast cancer, sponsored by AstraZeneca. Started Sep 2024; status: active.
02
Drugs
capivasertibfulvestrantpalbociclibribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232765.